You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COBIVEMU

Cancer Type: Skin, Melanoma      Intent: Palliative
Regimen Category: Evidence-Informed
Funding:
Exceptional Access Program
    cobimetinib - For combination therapy (with vemurafenib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or IV melanoma
Exceptional Access Program
    vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma

You might also be interested in